While GLP-1 agonists have grabbed investor attention for their potential as weight loss aids, these medicines also form a crucial component of a broader set of tools to address type 2 diabetes. With about 40 million people in the United States suffering from diabetes, and incidents of type 2 diabetes rising across multiple demographics, this core function of this class of medicines is still just as relevant as it was when these drugs first became available.
This is where medical device firms like DexCom Inc. (NASDAQ: DXCM) come into play. DexCom is not directly involved in the GLP-1 agonist space. Rather, it is known as a leader in continuous glucose monitoring (CGM) products, which are essential devices used by diabetic patients for health monitoring.
